MTEM(Delisted)
Molecular Templates·NASDAQ
--
--(--)
MTEM Profile
Molecular Templates, Inc.
A company that developing therapeutics for cancer including solid tumors
9301 Amberglen Blvd, Suite 100, Austin TX 78729
--
Molecular Templates, Inc., was incorporated in Delaware on October 17, 2001. The company is a biotechnology company focused on drug discovery and development for severe tissue hypoxia in the microenvironment of solid tumors and the bone marrow of patients with hematological malignancies. In June 2005, after conducting clinical trials in Europe, the company established a wholly-owned subsidiary in the UK — THLD Ltd. On February 3, 2012, the company obtained a global license and co-development agreement with Merck KGaA of Darmstadt, Germany, to jointly develop, produce and sell TH-302 (a small molecule drug for tissue hypoxia in Germany). Under the terms of the agreement, Merck obtains co-development rights and worldwide sales rights, and licenses the company to co-sell TH-302 in the United States. The company is a biotechnology company that uses its expertise in tumor microenvironment to discover and develop therapeutic agents that selectively target tumor cells to provide treatment for cancer patients. The company's advanced clinical investigational small molecule, TH-302, is currently being evaluated in two important third clinical trials and multiple early clinical trials. The Company has a global license and co-development agreement with Merck KGaA for TH-302 and co-sales in the United States.
